EDX Medical Group participating in “The Pub Test” Investor Evening

EDX Medical Group plc

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced its participation in “The Pub Test” Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at 6:00 PM.

The Company’s CEO, Dr Mike Hudson, will engage in a conversation designed especially for private investors. This informal setting offers an opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.

Commenting on the event, EDX Medical Group Dr Mike Hudson, said:

“We look forward to meeting and engaging with interested parties, shareholders, potential shareholders, and stakeholders, share our vision and answer any questions investors may have.”

All attendees will have the chance to network over drinks and a buffet.

To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

EDX Medical Group to launch highly accurate early detection test for testicular cancer

EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care.

EDX Medical Group raises £3.0 million to accelerate its prostate cancer ‘super test’

EDX Medical Group plc has secured £3 million by issuing 21.4 million new shares at 14p each, boosting its innovative prostate cancer diagnostic efforts.

EDX Medical Group signs master service agreement with The Royal Marsden

EDX Medical Group has secured a three-year master service agreement with The Royal Marsden NHS Foundation Trust to provide innovative diagnostic solutions for cancer care.

EDX Medical develops new ‘super test’ for prostate cancer

EDX Medical Group plc unveils a revolutionary AI-driven prostate cancer 'super test,' offering high accuracy and personalised treatment insights.

EDX Medical strengthens shareholder value by cancelling legacy warrants

EDX Medical Group (LON:EDX) cancels 5.37 million warrants, enhancing stability and reducing potential dilution for shareholders amidst robust growth.

EDX Medical receives support from high net worth, experienced healthcare investor

EDX Medical Group (AQSE:EDX) secures a £300,000 strategic investment from a Saudi healthcare investor to expand its digital diagnostic products.

Search

Search